Kabra Drugs Ltd. Announces Name Change, Strategic Acquisition, and Expansion Plans in EV Components, Steel Manufacturing, and Solar Energy Equipment

Kabra Drugs Ltd. held a Board meeting on 01st January 2026, where they approved several significant business items. The company has proposed a change of name to better reflect its new business direction and brand identity, subject to approval from the Ministry of Corporate Affairs and shareholders. The Board also granted in-principle approval for the acquisition of Vassmaan Automotive PVT LTD, which aligns with their strategic diversification into Medical Equipment & EV Components design and manufacturing sector. Additionally, Kabra Drugs Ltd. has signed an agreement with M/s. MR FRANCHISE to appoint 200 channel partners throughout the country, aiming to strengthen their market presence and distribution capabilities. The company also approved the amendment of the Main Objects clause of the Memorandum of Association (MOA) to include Electric Vehicle (EV) Components manufacturing and distribution, Steel manufacturing, and Solar Energy equipment manufacturing and power generation. These changes are subject to shareholder approval, which will be sought in an Extraordinary General Meeting (EGM).